1-Methyl-3-(1-methyl-1H-indol-3-yl)-4-(methylamino)-1H-pyrrole-2,5-dione (IM-20)
To a solution of IM-3 (54.2 mg, 0.197 mmol) in THF (1 mL) was added a 40% aqueous solution of methylamine (0.20 mL). The mixture was stirred for 24 h at room temperature, and then water was added.
The aqueous layer was extracted with ethyl acetate, and the combined organic layers were washed with brine. The organic layer was dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate = 4/1 ~ 2/1) to give the title compound (50. 3 
1-Methyl-3-(1-methyl-1H-indol-3-yl)-4-(propylamino)-1H-pyrrole-2,5-dione (IM-12)
To a solution of IM-3 (200 mg, 0.73 mmol) in CH2Cl2 (8 mL) was added n-propylamine (600 µL, 7.3 mmol), and the mixture was stirred at room temperature for 4 days. After evaporation of the solvent, the residue was purified by silica gel column chromatography (hexane/ethyl acetate = 4/1) to give IM-12 
4-(Butylamino)-1-methyl-3-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (IM-13)
Synthesized from IM- 3 
3-(2-Aminoethylamino)-1-methyl-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (IM-17)
To a solution of IM-4 (389 mg, 1.21 mmol) in THF (12 mL) was added 1,2-diaminoethane (809 µL, 12.1 mmol). The mixture was stirred for 9 days at room temperature, and then saturated aqueous NaHCO3 solution was added to it. The aqueous layer was extracted with ether and ethyl acetate, and the combined organic layer was washed with brine. The organic layer was dried over Na2SO4 and concentrated under reduced pressure. 
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3-(4-Hydroxybutylamino)-1-methyl-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (IM-91).
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HPLC analysis of purity
The purity of indolylmaleimide derivatives IM-17, 18, 19 was assessed by HPLC using a Waters HPLC system under two different conditions. 
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Biology
Cell culture HL-60 cells were maintained in RPMI 1640 medium supplemented with 100 U/mL penicillin, 100 µg/mL streptomycin, and 5% heat-inactivated fetal bovine serum (FBS). Jurkat cells were maintained in RPMI 1640 medium supplemented with 100 U/mL penicillin, 100 µg/mL streptomycin, and 10% heatinactivated fetal bovine serum (FBS). H9c2 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 100 U/mL penicillin, 100 µg/mL streptomycin, and 10% heat-inactivated fetal bovine serum (FBS). Cells were grown in a humidified incubator at 37 °C under 5% CO2/95% air. 
AlamarBlue assay
LDH assay
Lactate dehydrogenase (LDH) that leaked into the culture medium was measured with a Cytotoxicity detection kit PLUS (Roche Applied Science) according to the manufacturer's protocol. HL-60 cells were treated with test compounds and H2O2 (100 µM) in a 96-well plate according to the same method as 
Cell imaging
Phase-contrast images were taken with an Olympus IX71 microscope equipped with an Olympus DP70 cooled CCD camera. 
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Cell death inhibitors and inducers
Analysis of stability to liver metabolism
To Residual compound was quantified based on the peak area detected by UV (n = 3, three independent experiments). As shown in figure S1 , IM-12 and IM-54 were decreased rapidly and were not detected 
Langendorff isolated rat heart model
The isolated rat heart preparations used in this study have been described previously 3, 4 Male Sprague-Dawley rats were anesthetized with sodium pentobarbital. The experiments were 
Ischemia-reperfusion-induced arrhythmia model
S15
Thereafter, both ends of the nylon ligature were passed through a small polyethylene tube to make a coronary snare. The standard limb lead II electrocardiogram (ECG) was monitored by a cardiograph (ECG-6303, Nihon Kohden). ECG, blood pressure and heart rate data were collected by an ECG processor (Softron, Tokyo) and stored on the MO disk for further data processing. Myocardial ischemia was initiated by tightening the coronary snare and successful ischemia was confirmed by typical elevation of the ST segment in the ECG. At 5 min after the start of ischemia, reperfusion was initiated by releasing the snare. Ventricular fibrillation (Vf) after reperfusion was evaluated by ECG analysis based on the reported guideline 26 . Total duration of Vf was calculated as the sum of the duration of episodes that occurred within 10 min after reperfusion. 0.9% saline was used as a control. IM-17 was intravenously injected (1 ml/kg, over 1 min) at 5 min before ischemia (pre-ischemia treatment, 1 to 3 mg/kg) or at 1 min before reperfusion (post-ischemia treatment, 3 mg/kg).
As IM-54 was originally developed from ATP-competitive PKC inhibitor bisindolylmaleimide I (BM I) 5 , we previously analyzed its kinase-inhibitory activities against all PKC subtypes and confirmed that no PKC was inhibited by IM-54 1 . We also evaluated its inhibitory activities against various kinases related to cell-death signaling pathways. Protein kinase inhibition assays were performed using the KinaseProfiler service (Upstate USA, Inc.). Briefly, protein kinases were assayed for their ability to phosphorylate the appropriate peptide/protein substrates in the presence of 50 µM IM-54 and 100 µM or 10 µM ATP. Activities are given as mean percentages of those in control incubations (averages of duplicate determinations). IM-54 did not inhibit more than half of any kinase activity, indicating that IC50 values against all tested kinases were over 50 µM. Table S1 . KinaseProfiler assay of IM-54. The activity of various kinases was measured in the presence and absence of IM-54 (50 µM). ATP was present at 100 µM (left) or 10 µM (right).
KINOMEscan screening of IM-17 and IM-54
To examine the broad pattern of kinase inhibitory activities, KINOMEscan screening (DiscoverX Corp.)
was applied for IM-54 and IM-17 at 10 µM. KINOMEscan evaluated the binding affinity to kinases, which was determined based on the ATP site-dependent competition for beads-immobilized kinase inhibitors 6 . Activities are given as percentages of control values of bound kinases to beads-immobilized kinase inhibitors (averages of duplicate determinations). Less than 35 % of control at 10 µM indicates S17 significant inhibition of kinase. As shown in Table S2 , no significant inhibition of 467 kinases by IM-17
or IM-54 was observed, supporting the view that these compounds do not have kinase-inhibitory activity. TAK1  MAP3K7  98  93   TAOK1  TAOK1  100  78   TAOK2  TAOK2  88  89   TAOK3  TAOK3  98  94   TBK1  TBK1  85  78   TEC  TEC  96  100   TESK1  TESK1  96  100   TGFBR1  TGFBR1  92  100   TGFBR2  TGFBR2  85  97   TIE1  TIE1  100  74   TIE2  TEK  97  100   TLK1  TLK1  100  100   TLK2  TLK2  100  97   TNIK  TNIK  100  100   S27   TNK1  TNK1  95  100   TNK2  TNK2  98  100   TNNI3K  TNNI3K  100  98   TRKA  NTRK1  100  99   TRKB  NTRK2  100  100   TRKC  NTRK3  90  90   TRPM6  TRPM6  100  100   TSSK1B  TSSK1B  84  100   TSSK3  TSSK3  100 
